MedTrace Logo

A Real World Study of Regogfinib in HCC

NCT05557656 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2022-12-29

No results posted yet for this study

Summary

This is a non-interventional observational study with the primary objective of assessing the efficacy of regorafenib in patients with immediate or advanced stage HCC.

Conditions

Interventions

DRUG

Regorafenib 40 MG

participants who received the treatment of Regorafenib

Sponsors & Collaborators

  • The Central Hospital of Lishui City

    collaborator OTHER

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • Zhejiang University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Wuxi People's Hospital

    collaborator OTHER

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER

  • ZhuHai Hospital

    collaborator OTHER

  • Zhongda Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2023-12-31
Completion
2023-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05557656 on ClinicalTrials.gov